Skin & hair

The IL-17 Blockers and What They Clear

Save

When topical treatment and phototherapy stop being enough, IL-17 inhibitors are one of the biologic classes clinicians reach for — often the fastest-acting one for getting skin clear. This article covers what secukinumab and ixekizumab actually block, why they're frequently chosen when psoriatic arthritis is part of the picture, and the specific safety tradeoffs that come with interrupting IL-17 signaling.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What IL-17 Blockers Actually Block

Plaque psoriasis is driven substantially by an overactive Th17 immune pathway, and interleukin-17A (IL-17A) is one of the key signaling proteins that pathway uses to drive the rapid skin-cell turnover and inflammation that produce psoriasis plaques. Secukinumab and ixekizumab are monoclonal antibodies engineered to bind IL-17A directly and block it from signaling, which is a more targeted intervention than older biologic classes that block further upstream in the inflammatory cascade 1.

Because the target sits so directly in the pathway producing the plaques, IL-17 inhibitors are generally associated with some of the fastest and deepest skin clearance among the biologic classes used for psoriasis, which is a major reason they're a common choice when someone needs visible, timely results.

Where They Sit in the Treatment Ladder

IL-17 inhibitors are not usually where psoriasis treatment starts. Topical corticosteroids and steroid-sparing agents like vitamin D analogs remain the first step for limited, non-intertriginous plaques 2, and phototherapy — narrowband UVB, broadband UVB, or PUVA — is typically tried next or in parallel for more widespread disease before biologics enter the conversation 3. A biologic like an IL-17 inhibitor generally gets reached for when psoriasis covers a large body surface area, involves the scalp, palms, soles, or genitals in ways that hit quality of life hard, or hasn't responded adequately to topical and phototherapy approaches 1.

Within the biologic classes themselves, IL-17 inhibitors are one option among several — TNF inhibitors and IL-23 inhibitors are the other major families — and the choice among them depends on factors covered in more depth on choosing a psoriasis biologic, since speed of clearance, joint involvement, infection history, and dosing schedule all weigh differently for different people.

Why They're Often Reached for When Joints Are Involved Too

Up to roughly a third of people with psoriasis eventually develop psoriatic arthritis, and when that's already the case, the biologic choice has to work for the joints as well as the skin. IL-17 inhibitors are one of the biologic families with recognized efficacy in psoriatic arthritis, alongside TNF inhibitors and IL-23 inhibitors, which guideline groups weigh against small-molecule oral options like tofacitinib when choosing first-line therapy 4.

That dual efficacy is a meaningful practical advantage: it means a single medication can be prescribed to address both the skin and the joints rather than layering a second drug on top of psoriasis treatment once arthritis symptoms appear.

The Trade-off: Candida Infections

IL-17 plays a genuine, non-optional role in the body's mucosal defense against candida, the yeast responsible for oral thrush and vaginal yeast infections, which means blocking it comes with a real and well-documented increase in candida infection rates compared with placebo or with biologic classes that don't touch IL-17 1. Most cases are mild — mouth or vaginal symptoms that respond to standard antifungal treatment — but they're common enough that people starting an IL-17 inhibitor are typically told what the symptoms look like in advance rather than being surprised by them partway through treatment.

This tradeoff is specific to the IL-17 class in a way it isn't for TNF or IL-23 inhibitors, and it's one of the concrete differences that comes up when choosing among the psoriasis biologics rather than a generic "biologics have side effects" caveat.

Why the Rest of Your Health Picture Matters to the Choice

Psoriasis guideline groups recommend screening for and staying aware of the conditions that cluster with psoriasis — psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity among them — because treatment decisions don't happen in isolation from the rest of a person's health 5. Psoriasis severity itself has been linked to a higher burden of cardiovascular risk, tied to the systemic inflammation the disease produces, which is part of why clearing the skin is discussed as more than a cosmetic goal in guideline literature 6.

A history of inflammatory bowel disease is a specific flag for this class in particular: IL-17 inhibitors have been associated with new or worsening bowel inflammation in some patients, so that history is one of the things a clinician weighs before choosing this family over an alternative.

Secukinumab and Ixekizumab Aren't Interchangeable Brand Names

Both drugs are monoclonal antibodies that block IL-17A and both are used for the same range of conditions — plaque psoriasis, psoriatic arthritis, and a few related inflammatory conditions — so they're grouped together as the same drug class rather than treated as fundamentally different options 1. That doesn't make the choice between the two arbitrary in practice: dosing schedules differ, insurance formularies frequently cover one preferentially over the other, and how a person tolerated a similar injectable before can all factor into which specific drug a prescriber reaches for first.

A third IL-17 pathway drug, bimekizumab, blocks both IL-17A and IL-17F and has entered the same general class more recently, which is a reminder that this family is still evolving rather than fixed at two options. None of that changes the core tradeoff described above — faster clearance, weighed against a higher candida infection rate — since it applies across the class rather than to one specific drug within it.

What Starting Treatment Generally Involves

Both secukinumab and ixekizumab are self-injected, typically starting with more frequent doses over the first several weeks before moving to a maintenance schedule further apart — the exact schedule is set by a prescriber and varies by drug and by response. Before starting, screening usually includes a check for latent tuberculosis and a review of infection history, since biologics that alter immune signaling can allow a dormant infection to reactivate 1.

Most people see meaningful improvement within the first few months, and ongoing follow-up tracks both how well the skin and joints are responding and whether any of the known tradeoffs — candida symptoms, bowel symptoms, injection-site reactions — are showing up.

Common questions

Both are biologics used for moderate-to-severe psoriasis, but they interrupt the inflammatory pathway at different points. IL-17 inhibitors tend to act faster; IL-23 inhibitors block further upstream and are often dosed less frequently once on a maintenance schedule. The il-23 biologics for psoriasis are covered separately, since the practical differences matter for choosing between them.

No — most people never develop one, but the rate is meaningfully higher than with placebo or with biologic classes that don't affect IL-17. When it happens, it's usually mild oral or vaginal symptoms that clear with standard antifungal treatment rather than a reason to stop the biologic outright.

It's a real consideration rather than an automatic disqualifier. IL-17 inhibitors have been associated with new or worsening bowel inflammation in some patients, so a personal or strong family history of inflammatory bowel disease is something to raise directly, since it may steer the choice toward a different biologic class.

Yes — IL-17 inhibitors are one of the biologic families with recognized efficacy for psoriatic arthritis, which is a major reason they're often chosen when someone has both joint symptoms and skin plaques, letting one medication address both rather than needing two separate treatments.

Many people notice improvement within the first several weeks, with fuller results generally assessed around three to four months of treatment. Response speed and degree vary by individual, which is part of why follow-up visits track progress rather than assuming a fixed timeline for everyone.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What to Watch for on an IL-17 Inhibitor

  • —persistent white patches in the mouth, or vaginal itching and discharge, that could signal a candida infection
  • —new or worsening diarrhea, abdominal pain, or blood in the stool, which can signal bowel inflammation
  • —fever, night sweats, or a cough that doesn't resolve, which can signal a reactivated latent infection
  • —signs of a serious allergic reaction after an injection, such as facial or throat swelling or difficulty breathing

Facial or throat swelling, difficulty breathing, or any sign of a severe allergic reaction after an injection warrants calling 911 or going to an emergency room immediately rather than waiting to see if it passes.

This article describes IL-17 inhibitors as a drug class; it is not a substitute for a prescriber's assessment of whether one is appropriate for a specific person's psoriasis, joint disease, and overall health history.

References

  1. 1.American Academy of Dermatology; National Psoriasis Foundation (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology. PMID 30772098 ✓Supports the mechanism, treatment-ladder placement, and safety-monitoring profile of IL-17 inhibitors among biologic classes used for psoriasis, including infection screening and the candida infection tradeoff.
  2. 2.American Academy of Dermatology; National Psoriasis Foundation (2021). Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal of the American Academy of Dermatology. PMID 32738429 ✓Supports topical corticosteroids and steroid-sparing topical agents as the first-line step of the psoriasis treatment ladder that precedes biologic therapy.
  3. 3.American Academy of Dermatology; National Psoriasis Foundation (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy. Journal of the American Academy of Dermatology. PMID 31351884 ✓Supports phototherapy's placement in the treatment ladder before or alongside biologic therapy for more widespread psoriasis.
  4. 4.Singh JA, Guyatt G, Ogdie A, et al. (2019). 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Care & Research / Arthritis & Rheumatology. PMID 30499246 ✓Supports IL-17 inhibitors as one of the biologic families with recognized efficacy for psoriatic arthritis, weighed against TNF inhibitors, IL-12/23 inhibitors, and oral small-molecule options.
  5. 5.American Academy of Dermatology; National Psoriasis Foundation (2019). Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology. PMID 30772097 ✓Supports screening for and awareness of psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric comorbidity as part of psoriasis management, informing treatment choice.
  6. 6.Garshick MS, Ward NL, Krueger JG, Berger JS (2021). Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week. Journal of the American College of Cardiology. doi:10.1016/j.jacc.2021.02.009Supports the association between psoriasis severity and increased cardiovascular risk driven by systemic inflammation, informing why clearing skin disease is discussed as more than a cosmetic goal.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library